Scholarlink

Objective <p>To examine whether MRI with routine gadolinium-based contrast agent (GBCA) administration in the long-term surveillance of adult-type diffuse glioma identifies tumour progression earlier than T2-weighted (T2w) and/or T2w fluid-attenuated inversion recovery (FLAIR) MRI only.</p> Materials and methods <p>In this longitudinal retrospective multicentre cohort study patients with histopathologically confirmed adult-type diffuse glioma and at least two years survival after diagnosis in 2009–2010 were included. Progression was determined by the treating physician or during the multidisciplinary team meeting and defined as the moment a change in treatment or follow-up was required. The primary outcome was the proportion of patients that showed an increase of abnormalities on both contrast-enhanced T1-weighted (CET1w) and T2w/T2w-FLAIR at the time of progression. Chi-square testing was performed to analyse the relationship between the detection of progression on both scan sequences, with calculating the <i>Phi</i> coefficient to determine the degree of association.</p> Results <p>One hundred eight consecutive patients were included (58 male; 53 grade 2, 21 grade 3, 34 grade 4). Progression was present in 82 patients and was determined on both CET1w and T2w/T2w-FLAIR images in 59 patients (72.0%). In 20 patients (24.4%), progression was determined based solely on T2w/T2w-FLAIR abnormalities. Only three patients showed progression exclusively on CET1w (3.7%). There was a strong positive significant relationship between the detection of progression on both scan types (<i>p</i> &lt; 0.001; <i>Phi</i> = 0.467).</p> Conclusion <p>An increase in CET1w abnormalities was generally accompanied by an increase in T2w/T2w-FLAIR abnormalities, raising the question of whether routine administration of GBCA is always necessary for long-term survivors of glioma.</p> Key Points <p><Emphasis Type="BoldItalic">Question</Emphasis> Long-term survivors with glioma undergo many contrast-enhanced MRI scans, which involve a patient, financial, and environmental burden.</p> <p><Emphasis Type="BoldItalic">Findings</Emphasis> In almost all patients, an increase in T2w/T2w-FLAIR abnormalities was present at the time of tumour progression, mostly but not always accompanying contrast-enhancing findings.</p> <p><Emphasis Type="BoldItalic">Clinical relevance</Emphasis> T2w/T2-FLAIR MRI seems to detect glioma progression in long-term surviving patients similar to contrast-enhanced T1w MRI, raising the question of whether the routine administration of GBCA is necessary and justified in patients under long-term surveillance of glioma.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

How useful is contrast-enhanced MRI in the long-term surveillance of glioma? A multicentre retrospective longitudinal cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年2月28日

查看全文
  • Marcus Cakmak,
  • Sepehr Mohammadian,
  • Vera C. W. Keil,
  • Joost W. Schouten,
  • Philip C. de Witt Hamer,
  • Thijs van der Vaart,
  • Rutger K. Balvers,
  • Ivar J. H. G. Wamelink,
  • Frederik Barkhof,
  • Martin van den Bent,
  • Mark Vries,
  • Marion Smits

摘要

Objective

To examine whether MRI with routine gadolinium-based contrast agent (GBCA) administration in the long-term surveillance of adult-type diffuse glioma identifies tumour progression earlier than T2-weighted (T2w) and/or T2w fluid-attenuated inversion recovery (FLAIR) MRI only.

Materials and methods

In this longitudinal retrospective multicentre cohort study patients with histopathologically confirmed adult-type diffuse glioma and at least two years survival after diagnosis in 2009–2010 were included. Progression was determined by the treating physician or during the multidisciplinary team meeting and defined as the moment a change in treatment or follow-up was required. The primary outcome was the proportion of patients that showed an increase of abnormalities on both contrast-enhanced T1-weighted (CET1w) and T2w/T2w-FLAIR at the time of progression. Chi-square testing was performed to analyse the relationship between the detection of progression on both scan sequences, with calculating the Phi coefficient to determine the degree of association.

Results

One hundred eight consecutive patients were included (58 male; 53 grade 2, 21 grade 3, 34 grade 4). Progression was present in 82 patients and was determined on both CET1w and T2w/T2w-FLAIR images in 59 patients (72.0%). In 20 patients (24.4%), progression was determined based solely on T2w/T2w-FLAIR abnormalities. Only three patients showed progression exclusively on CET1w (3.7%). There was a strong positive significant relationship between the detection of progression on both scan types (p < 0.001; Phi = 0.467).

Conclusion

An increase in CET1w abnormalities was generally accompanied by an increase in T2w/T2w-FLAIR abnormalities, raising the question of whether routine administration of GBCA is always necessary for long-term survivors of glioma.

Key Points

Question Long-term survivors with glioma undergo many contrast-enhanced MRI scans, which involve a patient, financial, and environmental burden.

Findings In almost all patients, an increase in T2w/T2w-FLAIR abnormalities was present at the time of tumour progression, mostly but not always accompanying contrast-enhancing findings.

Clinical relevance T2w/T2-FLAIR MRI seems to detect glioma progression in long-term surviving patients similar to contrast-enhanced T1w MRI, raising the question of whether the routine administration of GBCA is necessary and justified in patients under long-term surveillance of glioma.

Graphical Abstract